Posted by Michael Wonder on 22 Oct 2020
Leo Pharma announces U.S. FDA approval for Enstilar (calcipotriene and betamethasone dipropionate) foam U.S. Prescribing Information update to include data in long-term use in plaque psoriasis treatment
22 October 2020 - U.S. Prescribing Information updated to include PSO-LONG clinical trial data concerning long-term use (52 weeks) of twice-weekly topical treatment with Enstilar (calcipotriene and betamethasone dipropionate) foam in adults with plaque psoriasis.
Leo Pharma today announced the U.S. FDA) has approved a U.S. Prescribing Information update for Enstilar (calcipotriene and betamethasone dipropionate) foam to include data on long-term use in adults with plaque psoriasis.
